These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9798467)

  • 41. Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low- and intermediate-risk papillary thyroid carcinoma patients not receiving radioactive iodine.
    Kashat L; Orlov S; Orlov D; Assi J; Salari F; Walfish PG
    Endocrine; 2016 Nov; 54(2):460-466. PubMed ID: 27189148
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma.
    Franceschi M; Kusić Z; Franceschi D; Lukinac L; Roncević S
    J Nucl Med; 1996 Mar; 37(3):446-51. PubMed ID: 8772642
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Differentiated thyroid cancer -- 2009].
    Konrády A
    Orv Hetil; 2011 Jan; 152(5):163-70. PubMed ID: 21247857
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Radio-iodine therapy in differentiated thyroid cancer: indications and procedures.
    Reiners C; Dietlein M; Luster M
    Best Pract Res Clin Endocrinol Metab; 2008 Dec; 22(6):989-1007. PubMed ID: 19041827
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Non-suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma.
    Böhm J; Kosma VM; Eskelinen M; Hollmen S; Niskanen M; Tulla H; Alhava E; Niskanen L
    Eur J Endocrinol; 1999 Nov; 141(5):460-7. PubMed ID: 10576761
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Incidence of regional recurrence guiding radicality in differentiated thyroid carcinoma.
    Simon D; Goretzki PE; Witte J; Röher HD
    World J Surg; 1996 Sep; 20(7):860-6; discussion 866. PubMed ID: 8678963
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer.
    Sawka AM; Brierley JD; Tsang RW; Thabane L; Rotstein L; Gafni A; Straus S; Goldstein DP
    Endocrinol Metab Clin North Am; 2008 Jun; 37(2):457-80, x. PubMed ID: 18502337
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
    Mazzaferri EL; Kloos RT
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma.
    Luster M; Lassmann M; Haenscheid H; Michalowski U; Incerti C; Reiners C
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3640-5. PubMed ID: 11061516
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Strategies of radioiodine ablation in patients with low-risk thyroid cancer.
    Schlumberger M; Catargi B; Borget I; Deandreis D; Zerdoud S; Bridji B; Bardet S; Leenhardt L; Bastie D; Schvartz C; Vera P; Morel O; Benisvy D; Bournaud C; Bonichon F; Dejax C; Toubert ME; Leboulleux S; Ricard M; Benhamou E;
    N Engl J Med; 2012 May; 366(18):1663-73. PubMed ID: 22551127
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients.
    Schlumberger M; Hitzel A; Toubert ME; Corone C; Troalen F; Schlageter MH; Claustrat F; Koscielny S; Taieb D; Toubeau M; Bonichon F; Borson-Chazot F; Leenhardt L; Schvartz C; Dejax C; Brenot-Rossi I; Torlontano M; Tenenbaum F; Bardet S; Bussière F; Girard JJ; Morel O; Schneegans O; Schlienger JL; Prost A; So D; Archambeaud F; Ricard M; Benhamou E
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2487-95. PubMed ID: 17426102
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
    Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
    Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The use of radioactive iodine in patients with papillary and follicular thyroid cancer.
    Wartofsky L; Sherman SI; Gopal J; Schlumberger M; Hay ID
    J Clin Endocrinol Metab; 1998 Dec; 83(12):4195-203. PubMed ID: 9851751
    [No Abstract]   [Full Text] [Related]  

  • 54. Drug therapy alternatives in the treatment of thyroid cancer.
    O'Doherty MJ; Coakley AJ
    Drugs; 1998 Jun; 55(6):801-12. PubMed ID: 9617595
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Surveillance after treatment of differentiated thyroid cancers].
    Mellière D; Berrahal D; Hindie E; Jeanguillaume C; Becquemin JP; Lange F
    Ann Chir; 2000 Nov; 125(9):856-60. PubMed ID: 11244593
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term follow-up of differentiated thyroid carcinoma in children and adolescents.
    Negre Busó M; García Burillo A; Simó Perdigó M; Galofré Mora P; Boronat de Ferrater M; Cuberas Borrós G; Sábado Álvarez C; Castell Conesa J
    J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1431-1441. PubMed ID: 32877364
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Controversies in the follow-up and management of well-differentiated thyroid cancer. New answers to old questions].
    Abós Olivares MD; Pesquera González C
    Rev Esp Med Nucl; 2005; 24(3):207-15. PubMed ID: 15847791
    [No Abstract]   [Full Text] [Related]  

  • 58. Embolization in combination with radioiodine therapy for bone metastases from differentiated thyroid carcinoma.
    Van Tol KM; Hew JM; Jager PL; Vermey A; Dullaart RP; Links TP
    Clin Endocrinol (Oxf); 2000 May; 52(5):653-9. PubMed ID: 10792347
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis.
    Sampson E; Brierley JD; Le LW; Rotstein L; Tsang RW
    Cancer; 2007 Oct; 110(7):1451-6. PubMed ID: 17705176
    [TBL] [Abstract][Full Text] [Related]  

  • 60. No adverse affect in clinical outcome using low preablation diagnostic (131)i activity in differentiated thyroid cancer: refuting thyroid-stunning effect.
    Yap BK; Murby B
    J Clin Endocrinol Metab; 2014 Jul; 99(7):2433-40. PubMed ID: 24762114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.